Remove Heart Failure Remove Innovation Remove Quality of Life
article thumbnail

Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research in Chronic Kidney Disease at ACC.25

DAIC

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25

article thumbnail

AHN Studying an Innovation that Improves Quality of Life and Cardiac Function in Heart Failure Patients

HCPLive

The AccuCinch® System, utilized by Allegheny General Hospital, offers a breakthrough approach to treating heart failure by targeting the left ventricle.

article thumbnail

New Treatment Options Available for Patients with Tricuspid Valve Disease

DAIC

Catheter-based procedures offer an alternative for patients who are not candidates for open-heart surgery. Studies estimate that severe regurgitation occurs in up to 4% of individuals 75 and older and is often linked with conditions like heart failure, atrial fibrillation or pulmonary hypertension.

article thumbnail

Allina Health’s Abbott Northwestern Hospital is First in Minnesota to Implant Barostim Therapy to Improve Symptoms of Heart Failure

DAIC

Barostim is the world’s first FDA-approved neuromodulation heart failure device, which works by stimulating baroreceptors — natural sensors located in the wall of the carotid artery, according to CVRx. I felt weak and tired all the time and knew I didn’t want to spend my life sitting in the living room chair. and Allina Health.

article thumbnail

AHN implants innovative device to manage central sleep apnea in heart failure patients

HCPLive

Allegheny Health Network (AHN) implants innovative device to manage central sleep apnea in heart failure patients, reducing mortality rise and improving quality of life.

article thumbnail

First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure Treatment

DAIC

(AskBio), a subsidiary of Bayer AG, have announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002, also known as NAN-101, for the treatment of congestive heart failure (CHF). It is estimated that 26 million worldwide are living with congestive heart failure.

article thumbnail

Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research

DAIC

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25